McCormick Guides FY26 Adj. EPS Below Estimates

McCormick initiated fiscal 2026 guidance, projecting adjusted EPS of $3.05–$3.13 and net sales growth of 13–17%, driven meaningfully by the Jan. 2, 2026 closing of a controlling stake in McCormick de Mexico; organic constant-currency sales are forecast at 1–3%. Management expects FX to boost net sales and adjusted EPS by about 1% each, while analysts on average expect $3.20 EPS and ~14.6% sales growth to $7.84 billion, leaving guidance broadly in line but slightly below consensus EPS.

Analysis

Market structure: McCormick (MKC) is the clear direct beneficiary — guidance shows FY26 net sales +13–17% driven by the Mexico deal while organic constant-currency growth is only 1–3%, implying limited underlying demand. Expect market-share gains in Mexico (estimate 100–300 bps over 12–24 months) and modest pricing power in branded spice categories, while private-label players and smaller regional spice suppliers face margin pressure. The deal raises leverage risk that could widen corporate bond spreads ~10–30 bps near-term; FX is a mild +1% tailwind to EPS but MXN volatility matters. Commodity spice prices (pepper, paprika) remain a wild card for gross margins over the next 6–18 months.

Risk assessment: Key tail risks are failed integration (operational/cultural), Mexican regulatory/tax surprises, or a >10% MXN depreciation which could flip the stated FX tailwind into a ~5–8% EPS headwind depending on revenue mix. Immediate risk window is the next 1–10 trading days (share reaction to conservative guidance vs. analyst $3.20), short-term risk is execution over the next 2 quarters as synergies/one-offs surface, and long-term outcomes materialize over 12–36 months. Hidden dependencies include IT/supply-chain integration, cross-border pricing contracts, and earnout or minority-holder disputes.

Trade implications: Tactical: establish a 2–3% long position in MKC on a >5% intraday post-guidance dip within 30 days, with a 12% stop; alternatively, buy a 9–12 month LEAP call ~10% OTM to capture upside if synergies show in next two quarters. Pair trade: go long MKC / short KHC (Kraft Heinz) equal-dollar to isolate branded-spice exposure vs private-label margin risk, monitor P&L monthly. Options: sell 90-day covered calls (10–15% OTM) if holding stock to harvest yield; buy 4–6 month 5–8% OTM protective puts (cost ~1–2% of position) if nervous about integration risk.

Contrarian angles: Street may underappreciate cross-sell upside — a successful integration could add $0.10–0.20 to EPS in 18–36 months from pricing and SKU expansion, creating asymmetric upside versus the modest near-term organic outlook. Conversely, the market also might underprice one-time integration costs of $0.15–0.25 EPS in year one; watch Q1 cadence and Mexican revenue disclosure as the binary catalysts. Historical parallels (regional brand tuck-ins) suggest a 12–24 month runway to realized margin improvement, so size positions accordingly and reassess after two quarterly reports.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in MKC on a >5% intraday decline within the next 30 days; set a trailing stop at -12% and plan to reassess after two quarters (to monitor synergy realization and organic growth).
• Buy 1-year LEAP calls on MKC ~10% OTM (expiry 9–12 months) sized at 0.5–1% of portfolio for asymmetric upside if Mexico synergies and cross-sells accelerate; cap downside to premium paid.
• Initiate an equal-dollar pair trade: long MKC / short KHC (Kraft Heinz) sized to be beta neutral, horizon 6–12 months to play branded spice exposure vs private-label pressure; rebalance monthly and trim if MKC outperforms >15%.
• If holding MKC stock, sell 90-day covered calls 10–15% OTM to generate income given muted organic growth; simultaneously buy 4–6 month puts 5–8% OTM as a cost-effective hedge (target hedge cost <2% of position).